17 research outputs found
Values and perceptions of landowners within remaining breeding territories of Eurasian Curlew Numenius arquata in Ireland
International audienceHabitat loss and degradation have been identified as some of the main threats to breeding Curlew (Numenius arquata) across much of Europe. In Ireland, marginal habitats such as rough or wet grasslands and peatlands have been fragmented or degraded by activities including afforestation, drainage and intensification. The management implemented by landowners directly affects Curlew breeding territories. However, the values and perceptions held by landowners whose lands contain Curlew breeding territories, or the factors driving the decisions behind farming practices in these areas are rarely considered when looking at the causes of changes in these bird populations. This study, as part of the Curlew Conservation Programme established in 2017, gathered data through the distribution of questionnaires to landowners found within three kilometres of Curlew breeding territories in Ireland. In this study, we identify the current land uses being employed in Curlew breeding territories, and query future projections of land use in these areas. We investigate landownersâ perceptions of the requirements to sustain favourable environments for breeding Curlew. We also explore landowner values with respect to farming. The landowners in this study identified habitat loss and predation as the main drivers for Curlew declines. The majority of farming systems in this study were cattle rearing, the sustainability of which is under threat across Ireland. The results indicate that these landowners are not financially motivated, however, the availability of financial aid and expert advice are listed by landowners as requirements for traditional farming practices to continue. These results give an insight to the lifestyle, values and perceptions owners of land adjacent or within Curlew breeding territories. This information can be used to design Curlew conservation programmes that align with these values
Sa1794 - Utility of Faecal Calprotectin to Assess Crohn's Disease Activity in Patients with an Ileostomy
Su1867 â Sustainanility of Biologic Therapies is Less in Ulcerative Colitis that Crohns Disease Patients Independent of Prior Biologic Experience
Tu1819 - Deep Immunophenotyping Reveals a Role for Mucosal Associated Invariant T (MAIT) Cells in the Response to Antitnf Treatment in Crohn's Disease
Implementation of BSG/ACPGBI/PHE polypectomy surveillance guidelines safely reduces the burden of surveillance in a screening cohort: a virtual model study
Objective To evaluate the impact of British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England (BSG/ACPGBI/PHE) 2019 polypectomy surveillance guidelines within a national faecal immunochemical test-based bowel cancer screening (BS) cohort on surveillance activity and detection of pathology by retrospective virtual application.Design A retrospective review of BS colonoscopies performed in 2015â2016 with 5 years prospective follow-up in single institution. Index colonoscopies were selected. Incomplete colonoscopies were excluded. Histology of all resected polyps was reviewed. Surveillance intervals were calculated according to BSG/ACPGBI/PHE 2019 guidelines and compared with pre-existing âEuropean Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosisâ (EUQA 2013). Total number of colonoscopies deferred by virtual implementation of BSG/ACPGBI/PHE 2019 guidelines were calculated. Pathology identified on procedures that would have been deferred was reviewed.Results Total number of index BS colonoscopies performed in 2015â2016 inclusive was 890. 115 were excluded (22âno caecal intubation, 51 inadequate bowel preparation, 56 incomplete polyp clearance). N=509 colonoscopies were scheduled within a 5-year interval following index colonoscopy surveillance rounds based on EUQA guidelines. Overall, volume of surveillance was significantly reduced with retrospective application of BSG/ACPGBI/PHE 2019 guidelines (n=221, p<0.0001). No cancers were detected within the âpotentially deferredâ procedures who attended for follow-up (n=330) with high-risk findings found in<10% (n=30) of colonoscopies within the BSG/ACPGBI/PHE cohort.Conclusion BSG/ACPGBI/PHE 2019 guidelines safely reduce the burden of colonoscopy demand with acceptable pathology findings on deferred colonoscopies
Targeted detection and quantitation of histone modifications from 1,000 cells.
Histone post-translational modifications (PTMs) create a powerful regulatory mechanism for maintaining chromosomal integrity in cells. Histone acetylation and methylation, the most widely studied histone PTMs, act in concert with chromatin-associated proteins to control access to genetic information during transcription. Alterations in cellular histone PTMs have been linked to disease states and have crucial biomarker and therapeutic potential. Traditional bottom-up mass spectrometry of histones requires large numbers of cells, typically one million or more. However, for some cell subtype-specific studies, it is difficult or impossible to obtain such large numbers of cells and quantification of rare histone PTMs is often unachievable. An established targeted LC-MS/MS method was used to quantify the abundance of histone PTMs from cell lines and primary human specimens. Sample preparation was modified by omitting nuclear isolation and reducing the rounds of histone derivatization to improve detection of histone peptides down to 1,000 cells. In the current study, we developed and validated a quantitative LC-MS/MS approach tailored for a targeted histone assay of 75 histone peptides with as few as 10,000 cells. Furthermore, we were able to detect and quantify 61 histone peptides from just 1,000 primary human stem cells. Detection of 37 histone peptides was possible from 1,000 acute myeloid leukemia patient cells. We anticipate that this revised method can be used in many applications where achieving large cell numbers is challenging, including rare human cell populations
Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohnâs Disease Treated Until 33 Weeks of Gestation
Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)
Background and Aims
Evidence suggests patients with inflammatory bowel disease [IBD] receiving TNF antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and of various medications for treatment of IBD on antibody responses to vaccination against COVID-19.
Methods
Patients with IBD [n = 270] and healthy controls [HC, n = 116] were recruited prospectively, and quantitative antibody responses were assessed following COVID-19 vaccination. The impact of IBD and of medications for treatment of IBD on vaccine response rates was investigated.
Results
Of HC, 100% seroconverted following complete vaccination with two vaccine doses; 2% of patients with IBD failed to seroconvert. Median anti-spike protein [SP] immunoglobulin [Ig]G levels following complete vaccination in our IBD cohort was significantly lower than among HC [2613 AU/mL versus 6871 AU/mL, p â€0.001]. A diagnosis of IBD was independently associated with lower anti-SP IgG levels [ÎČ coefficient -0.2, p = 0.001]. Use of mRNA vaccines was independently associated with higher anti-SP IgG levels [ÎČ coefficient 0.25, p â€0.001]. Patients with IBD receiving TNF inhibitors had significantly lower anti-SP IgG levels [2445 AU/mL] than IBD patients not receiving TNF inhibitors [3868 AU/mL, p â€0.001]. Patients with IBD not receiving TNF inhibitors still showed attenuated responses compared with HC [3868 AU/mL versus 8747 AU/mL, p = 0.001].
Conclusions
Patients with IBD have attenuated serological responses to SARS-CoV-2 vaccination. Use of anti-TNF therapy negatively affects anti-SP IgG levels further. Patients who do not seroconvert following vaccination are a particularly vulnerable cohort. Impaired responses to vaccination in our study highlight the importance of booster vaccination programmes for patients with IBD.</p